Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety and Efficacy Evaluation of CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma

NCT03118180 is registered in ClinicalTrials.gov with Zhejiang University as lead sponsor.

NCT NCT03118180
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03118180 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety and Efficacy Evaluation of CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma
Lead sponsor
Zhejiang University
Phase
Phase 1/2
Overall status
Unknown status
Start date
April 5, 2017
Completion date
December 31, 2020
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma